A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PTG-200 in Normal Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs PTG 200 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Acronyms PTG-200-01
- Sponsors Protagonist Therapeutics
- 29 Nov 2017 Planned initiation date changed from 30 Oct 2017 to 8 Nov 2017.
- 09 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Protagonist Therapeutics media release.
- 10 Oct 2017 Status changed from planning to not yet recruiting.